Maternal & Child Health Research Institute (MCHRI)
Showing 701-710 of 996 Results
-
James Priest
Adjunct Clinical Assistant Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsThe Priest lab seeks a better understanding of the genetics and pathogenesis of congenital heart disease using translational genomics, big-data, and vertebrate models of cardiac development.
-
Lance Prince
Philip Sunshine, MD, Professor of Neonatology
BioLawrence (Lance) S. Prince, MD, PhD, is the Philip Sunshine Endowed Professor of Pediatrics at Stanford School of Medicine. Dr. Prince was previously a Professor of Pediatrics and Chief of the Division of Neonatology at the University of California, San Diego and Rady Children’s Hospital, San Diego.
Dr. Prince has a long and distinguished career mentoring clinical and scientific trainees and students, many of whom have gone on to establish their own successful careers as academic physician investigators. As a physician scientist, Dr. Prince leads a basic science laboratory focusing on the mechanisms regulating developmental immunology and lung injury and repair. Dr. Prince received a Bachelor of Science in Chemistry from University of Miami, an MD/PhD with a focus in Cell Biology from University of Alabama at Birmingham, and postdoctoral fellowship, Pediatrics residency, and Neonatal-Perinatal Medicine Fellowship training at the University of Iowa. Before arriving in California, Dr. Prince was an Associate Professor of Pediatrics at Vanderbilt University.
Dr. Prince’s research interests include the molecular and cellular mechanisms controlling lung development and the maturation of the fetal and neonatal immune systems. He has a particular clinical interest in managing and treating neonatal lung diseases, especially bronchopulmonary dysplasia (BPD) in babies born extremely preterm. Dr. Prince’s research team focuses primarily on the development of innate immunity during fetal life as it impacts health and disease in preterm infants. The laboratory is investigating how microbes including Group B streptococcus exploit the unique features of neonatal macrophages to avoid immune detection and cause disease, as well as leading a number of clinical and translational investigations. -
Charles G. Prober, MD
Professor of Pediatrics (Infectious Diseases) and, by courtesy, of Microbiology and Immunology
Current Research and Scholarly InterestsMy research interest is in the epidemiology, pathophysiology, prevention, and treatment of infections in children. Much of this research has focused on viral infections, especially those caused by herpes simplex virus (HSV). I have conducted a number of studies concerned with the epidemiology of HSV-2 infections in pregnant women, their partners, and neonates.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
Jochen Profit
Wendy J. Tomlin-Hess Endowed Professor
Current Research and Scholarly InterestsFunded by NIH R01 grants:
1) Development and application of composite measure of NICU quality - Baby-MONITOR
2) High reliability, safety culture and caregiver resilience as modifiers of care quality
3) Modifiable racial/ethnic disparities in quality of care delivery
4) Effectiveness of regionalized care delivery systems for preterm newborns -
Stephanie Pun, MD
Clinical Associate Professor, Orthopaedic Surgery
Current Research and Scholarly InterestsDr. Pun specializes in the treatment of complex hip disorders with surgical hip preservation options for children, adolescents, and adults. Her goal is to enhance hip function in active individuals and to prevent the early development of hip osteoarthritis.
-
Stanley Qi
Associate Professor of Bioengineering
BioStanley Qi (publishing as Lei S. Qi) is a pioneer in the field of genome engineering and the architect of the foundational technologies that transitioned CRISPR from a "cutting" tool into a universal platform for Programmable Biology. As the inventor of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), Qi established the first methods for the precise, reversible, and targeted regulation of the human genome without altering the DNA sequence.
The Qi Lab integrates scalable genomic perturbation with live-cell and super-resolution imaging and computation-guided design to redefine the boundaries of cellular control. Under Dr. Qi’s leadership, the group has fundamentally expanded the genome engineering toolbox, evolving CRISPR from a single editing tool into a multidimensional platform for the precise control of dynamic and spatial cell states. This work includes establishing foundational technologies and architectures for precise epigenetic editing, multiplexed regulation of the transcriptome, programmable 3D genome organization, and spatial control of RNA logistics. By pioneering real-time visualization of chromatin dynamics and RNA in living cells, the lab provides an unprecedented window into the fundamental "control principles of life."
This principle-driven technology lineage has moved into the clinic, with the lab's compact epigenetic editor currently in first-in-human clinical testing for FSHD muscular dystrophy (NCT06907875). This milestone represents a core mission of the lab: translating foundational engineering into next-generation therapeutics that act predictably as dynamic, complex systems.
Beyond single-cell control, the Qi Lab is building a framework for synthetic cell–cell communication, with a particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors.
By integrating computational design with experimental biology, Dr. Qi aims to identify the generalizable rules linking molecular programs to systems-level physiology. He is a Chan Zuckerberg Biohub Investigator and an Institute Scholar at the Sarafan ChEM-H, and is dedicated to shaping the technical and ethical frameworks that will define the future of human genome engineering.
